 Ocugen Inc NASDAQ: OCGN says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart autologous chondrocyte-derived neocartilage. Recently, the FDA granted a Regenerative Medicine Advanced Therapy RMAT designation to. 